ReviewDrug design, development and therapy2022
Chikungunya Vaccine Candidates: Current Landscape and Future Prospects.
Review in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Review
- From symptom management to immune prevention: a comprehensive review of chikungunya treatment and vaccine development.Folia microbiologica · 2026Review
- Eupatorium perfoliatum Counteracts TNF-α Mediated Pathogenesis in Chikungunya Virus Infection.Applied biochemistry and biotechnology · 2026Article
- The impact of variations in the chikungunya genome on the clinical manifestations and transmission of the disease.Journal of family medicine and primary care · 2025Review
- Outbreak and epidemic of Getah virus infection in swine by virulence-enhanced GIII variant in Henan, central China in 2024.Virulence · 2025Article
- Exploiting the chikungunya virus capsid protein: a focused target for antiviral therapeutic development.Archives of virology · 2025Review
- CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection.Signal transduction and targeted therapy · 2025Article
- Review
- Advancements and Challenges in Addressing Zoonotic Viral Infections with Epidemic and Pandemic Threats.Viruses · 2025Review
- Revolutionizing Chikungunya Vaccines: mRNA Breakthroughs With Molecular and Immune Simulations.Bioinformatics and biology insights · 2025Article
- Pathogenicity and virulence of chikungunya virus.Virulence · 2024Review
- Chikungunya Virus Vaccines: A Review of IXCHIQ and PXVX0317 from Pre-Clinical Evaluation to Licensure.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis.Vaccines · 2024Review
- Live-attenuated CHIKV vaccine with rearranged genome replicates in vitro and induces immune response in mice.PLoS neglected tropical diseases · 2024Article
- Review
- Strategic considerations on developing a CHIKV vaccine and ensuring equitable access for countries in need.NPJ vaccines · 2023Review
- Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity.International journal of molecular sciences · 2023Article
- An Overview of Indian Biomedical Research on the Chikungunya Virus with Particular Reference to Its Vaccine, an Unmet Medical Need.Vaccines · 2023Review
- Article
- Maxizyme-mediated suppression of chikungunya virus replication and transmission in transgenicFrontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) is an alphavirus that has spread globally in the last twenty years. Although mortality is rather low, infection can result in debilitating arthralgia that can persist for years. Unfortunately, no treatments or preventive vaccines are currently licensed against CHIKV infections. However, a large range of promising preclinical and clinical vaccine candidates have been developed during recent years. This review will give an introduction into the biology of CHIKV and the immune responses that are induced by infection, and will summarize CHIKV vaccine development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.